Abstract: Disclosed are compositions and methods for targeted treatment of cancer. The present disclosure provides chimeric antigen receptors and cells expressing such chimeric antigen receptors. In certain embodiments, engineered cells expressing the chimeric antigen receptors are specific for a low density cancer antigen or peptide in groove antigen.

Abstract: A novel maize variety designated X08V966 and seed, plants and plant parts thereof are produced by crossing inbred maize varieties. Methods for producing a maize plant by crossing hybrid maize variety X08V966 with another maize plant are disclosed. Methods for producing a maize plant containing in its genetic material one or more traits introgressed into X08V966 through backcrossing or genetic transformation, and to the maize seed, plant and plant part produced thereby are described. Maize variety X08V966, the seed, the plant produced from the seed, and variants, mutants, and minor modifications of maize variety X08V966 are provided. Methods for producing maize varieties derived from maize variety X08V966 and methods of using maize variety X08V966 are disclosed.

Abstract: The present application provides an aft plate removal tool for servicing a combustor. The combustor includes an end cover, an aft plate downstream of the end cover, and a number of tubes extending through the aft plate. The aft plate removal tool includes a base plate and a threaded rod. The base plate is attached to the end cover. Rotation of the threaded rod advances the threaded rod against the aft plate until the threaded rod pushes the aft plate off of the tubes.

Abstract: A novel maize variety designated 1PGRW56 and seed, plants and plant parts thereof are provided. Methods for producing a maize plant comprise crossing maize variety 1PGRW56 with another maize plant are provided. Methods for producing a maize plant containing in its genetic material one or more traits introgressed into 1PGRW56 through backcross conversion and/or transformation, and to the maize seed, plant and plant part produced thereby are provided. Hybrid maize seed, plants or plant parts are produced by crossing the variety 1PGRW56 or a locus conversion of 1PGRW56 with another maize variety.

Abstract: The present disclosure relates to IL2 agonists with improved therapeutic profiles.

Abstract: The present disclosure relates to IL2 agonists with improved therapeutic profiles.

Abstract: A novel maize variety designated 1PTJY93 and seed, plants and plant parts thereof are provided. Methods for producing a maize plant comprise crossing maize variety 1PTJY93 with another maize plant are provided. Methods for producing a maize plant containing in its genetic material one or more traits introgressed into 1PTJY93 through backcross conversion and/or transformation, and to the maize seed, plant and plant part produced thereby are provided. Hybrid maize seed, plants or plant parts are produced by crossing the variety 1PTJY93 or a locus conversion of 1PTJY93 with another maize variety.

Abstract: Examples of lattice structures are described herein. In some examples, a heat exchanger may include a three-dimensional (3D) lattice structure. In some examples, the heat exchanger may include a spiral structure transecting the 3D lattice structure. In some examples, the spiral structure is to mix fluid to pass through the 3D lattice structure.

Abstract: The present disclosure relates to IL2 agonists with improved therapeutic profiles.

Abstract: B-cell maturation antigen (BCMA) is expressed on malignant plasma cells. The present invention provides BCMA-specific chimeric antigen receptors and cells expressing such chimeric antigen receptors. In certain embodiments, engineered cells expressing the chimeric antigen receptors of the present invention are capable of inhibiting the growth of tumors expressing BCMA. The engineered cells of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced BCMA-targeted immune response is desired and/or therapeutically beneficial. For example, engineered cells expressing the BCMA-specific chimeric antigen receptors of the invention are useful for the treatment of various cancers, including multiple myeloma.

Abstract: The present disclosure relates to a three-dimensional printing kit comprising: a powder bed material comprising polymer particles; a fusing agent comprising a radiation absorber and a liquid carrier; and a magnetic marking agent comprising magnetic nanoparticles, a humectant and a liquid carrier, wherein the concentration of magnetic nanoparticles is 5 to 70 weight % based on the total weight of the magnetic agent. The present disclosure also relates to a method of three-dimensional (3D) printing a 3D printed object. The method comprises: selectively applying a magnetic marking agent onto powder bed material, wherein the powder bed material comprises polymer particles, and wherein the magnetic marking agent comprises magnetic nanoparticles and a liquid carrier; selectively fusing the powder bed material, such that the magnetic nanoparticles are incorporated in the 3D printed object in a predetermined arrangement that forms a detectable marker in the 3D printed object.

Abstract: The present disclosure is for a system and a method for artificial intelligence (AI) based review of radiologic images as they are being read by a radiologist. The AI review is performed through the use of screen sharing and screen capture approaches allowing an AI model to analyze images without direct access to the raw image files. The AI review may compare user documented findings with AI model-based findings in order to identify discrepancies between the two. The discrepancies can be used as feedback for retraining the model and/or as feedback to the user to aid in education or track and/or improve an individual's review characteristics.

Abstract: B-cell maturation antigen (BCMA) is expressed on malignant plasma cells. The present invention provides BCMA-specific chimeric antigen receptors and cells expressing such chimeric antigen receptors. In certain embodiments, engineered cells expressing the chimeric antigen receptors of the present invention are capable of inhibiting the growth of tumors expressing BCMA. The engineered cells of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced BCMA-targeted immune response is desired and/or therapeutically beneficial. For example, engineered cells expressing the BCMA-specific chimeric antigen receptors of the invention are useful for the treatment of various cancers, including multiple myeloma.

Abstract: The present disclosure relates to IL2 agonists with improved therapeutic profiles.

Abstract: A method of transmitting a set of conforming data frames within an avionics system. The avionics system including a Flight Management System (FMS) and an avionics device. The method including generating, via the avionics device, at least one specialized message, transmitting, via the avionics device, the at least on specialized message, generating, via the avionics device, the set of conforming data frames, and transmitting, via the avionics device, at least a subset of the set of conforming data frames. The method comprising receiving, via the FMS, at least one transmission including at least one of the specialized header frame or the set of conforming data frames from the avionics device.

Abstract: Provided herein are methods of making a training aid for detecting a biohazard, and related devices and methods of using the device, including a canine training aid. The devices are made by positioning a polymer layer in proximity and physically separated from a biological material, so that volatile organic compounds contact and bind or infuse the polymer layer. The device is made render-safe by inactivating the infused polymer layer, such as by heating to a temperature sufficient to inactivate biological agents on or in the analyte-infused polymer layer. The device can be stored in a substantially air-tight configuration for subsequent use in training, such as canine and/or or artificial detectors.

Abstract: Disclosed are compositions and methods for targeted treatment of cancer. The present disclosure provides chimeric antigen receptors and cells expressing such chimeric antigen receptors. In certain embodiments, engineered cells expressing the chimeric antigen receptors are specific for a low density cancer antigen or peptide in groove antigen.

Abstract: The present disclosure is for a system and a method for artificial intelligence (AI) based review of radiologic images as they are being read by a radiologist. The AI review is performed through the use of screen sharing and screen capture approaches allowing an AI model to analyze images without direct access to the raw image files. The AI review may compare user documented findings with AI model-based findings in order to identify discrepancies between the two. The discrepancies can be used as feedback for retraining the model and/or as feedback to the user to aid in education or track and/or improve an individual's review characteristics.

Abstract: The present disclosure describes three-dimensional printing kits, three-dimensional printing systems, and methods of making three-dimensional printed objects. In one example, a three-dimensional printing kit can include a build material and a binding agent. The build material can include particles of copper or a copper alloy. The binding agent can include water, copper (II) nitrate or a hydrate thereof, and a reaction inhibition additive. The additive can be a copper oxide etchant, a water-soluble phosphate-containing compound, or a combination thereof.

Abstract: A three-dimensional printing kit can include a particulate build material with from about 80 wt % to 100 wt % copper-containing build particles having a D50 particle size distribution value from about 1 ?m to about 150 ?m, a binding agent including a build binder to apply to particulate build material layers to form a green body object, and a shaping composition to apply to a surface of the green body object and to control green body object deformation. The shaping composition can include from about 10 wt % to about 80 wt % liquid vehicle and from about 20 wt % to about 90 wt % metal shaping particles having a D50 particle size distribution value from about 100 nm to about 100 ?m. The metal shaping particles can be smaller than the copper-containing build particles.